Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Relationship between COVID-19 Severity and Plasma Levels of Vascular Endothelial Growth Factor (VEGF)

Author(s): Mitra Samareh Fekri, Elham Barfzade*, Ahmad Shafahi, Mehrdad Farokhnia, Fatemeh Karami Robati, Sajjadeh Movahedinia and Shariar Dabiri

Volume 20, Issue 1, 2024

Published on: 13 November, 2023

Page: [13 - 19] Pages: 7

DOI: 10.2174/011573398X248003231106092908

Price: $65

Abstract

Background: This study aimed to assess the relationship between COVID-19 severity and the plasma levels of vascular endothelial growth factor.

Methods: This cross-sectional study was conducted on 86 patients with COVID-19. A 5 ml venous blood sample was taken on the first day of hospitalization. VEGF was measured with the ELISA method using the Hangzhou East biopharm VEGF ELIZA Kit.

Results: The mean age of patients was 56 ± 15 years. The mean plasma level of VEGF was 2877.07 ± 104.77 ng/ml. There was no significant relationship between VEGF levels and COVID-19 severity (P = 0.55). The percentage of pulmonary infiltration > 50 in the severe group (72.7%) was higher than that of the non-severe group (2.4%) (P = 0.001). There was a significant relationship between COVID-19 severity and the levels of LDH, neutrophil/lymph ratio, and CRP. Regarding medications, remdesivir was used more in the severe group (70.5%) than in the non-severe group (45.2%) (P = 0.018).

Conclusion: Although plasma VEGF levels were higher in the severe group than in the non-severe group, no significant relationship was found between the plasma level of VEGF and COVID-19 severity, which might be due to the small sample size. VEGF may be a valuable scientific marker, but in this study, it was not as useful as other markers in identifying COVID-19 severity. In addition, there was a direct and significant relationship between COVID-19 severity and the inflammatory markers LDH, neutrophil/lymph, and CRP. Therefore, measurement of inflammatory markers can assist in the early identification and prediction of severity and disease progression in COVID-19.

« Previous Next »
Graphical Abstract

[1]
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019 N Engl J Med 2020; 382(8): 727-33.
[PMID: 31978945]
[2]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[3]
Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-44.
[http://dx.doi.org/10.1038/s41564-020-0695-z] [PMID: 32123347]
[4]
WHO. WHO Director-General’s remarks at the media briefing on 2019-nCoV. 2020. Available From: https://www who int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-
[5]
Fekri MS, Barfzade E, Farokhnia M, et al. Investigating COVID-19 Severity Based on Serum Apelin-17 Levels and Inflammatory Mediators. Curr Respir Med Rev 2022; 18(1): 65-71.
[http://dx.doi.org/10.2174/1573398X18666220210145349]
[6]
de Vries AAF. SARS-CoV-2/COVID-19: A primer for cardiologists. Neth Heart J 2020; 28(7-8): 366-83.
[http://dx.doi.org/10.1007/s12471-020-01475-1] [PMID: 32671650]
[7]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[8]
WHO. Coronavirus disease (COVID-19) pandemic 2021. 2021. Available From: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[9]
Lee I-C, Huo T-I, Huang Y-H. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc 2020; 83(6): 521-3.
[10]
Patel KP, Patel PA, Vunnam RR, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol 2020; 128: 104386.
[http://dx.doi.org/10.1016/j.jcv.2020.104386] [PMID: 32388469]
[11]
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020; 73(3): 566-74.
[12]
Gallo Marin B, Aghagoli G, Lavine K, et al. Predictors of COVID -19 severity: A literature review. Rev Med Virol 2021; 31(1): 1-10.
[http://dx.doi.org/10.1002/rmv.2146] [PMID: 32845042]
[13]
WHO. 2020. Available From: https://apps.who. int/iris/bitstream/handle/10665/332196/WHO-2019-nCoVclinical-2020.5-eng.pdf
[14]
Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature 2020; 583(7816): 437-40.
[http://dx.doi.org/10.1038/s41586-020-2355-0] [PMID: 32434211]
[15]
Mura M, Han B, Andrade CF, et al. The early responses of VEGF and its receptors during acute lung injury: Implication of VEGF in alveolar epithelial cell survival. Crit Care 2006; 10(5): R130.
[http://dx.doi.org/10.1186/cc5042] [PMID: 16968555]
[16]
Ourradi K, Blythe T, Jarrett C, Barratt SL, Welsh GI, Millar AB. VEGF isoforms have differential effects on permeability of human pulmonary microvascular endothelial cells. Respir Res 2017; 18(1): 116.
[http://dx.doi.org/10.1186/s12931-017-0602-1] [PMID: 28578669]
[17]
Mitchell WB. Thromboinflammation in COVID-19 acute lung injury. Paediatr Respir Rev 2020; 35: 20-4.
[PMID: 32653469]
[18]
Colantuoni A, Martini R, Caprari P, et al. COVID-19 sepsis and microcirculation dysfunction. Front Physiol 2020; 11: 747.
[http://dx.doi.org/10.3389/fphys.2020.00747] [PMID: 32676039]
[19]
WHO. 2020. Available From: www.who.int/publications/i/item/clinical-management-of-covid-19
[20]
Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: Correlation with disease severity and short-term prognosis. Eur Radiol 2020; 30(12): 6808-17.
[http://dx.doi.org/10.1007/s00330-020-07033-y] [PMID: 32623505]
[21]
Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H. VEGF-D: A novel biomarker for detection of COVID-19 progression. Crit Care 2020; 24(1): 373.
[http://dx.doi.org/10.1186/s13054-020-03079-y] [PMID: 32576222]
[22]
Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA 1998; 95(26): 15809-14.
[http://dx.doi.org/10.1073/pnas.95.26.15809] [PMID: 9861052]
[23]
Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol 2000; 22(6): 657-64.
[http://dx.doi.org/10.1165/ajrcmb.22.6.3779] [PMID: 10837361]
[24]
Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004; 10(10): 1095-103.
[http://dx.doi.org/10.1038/nm1105] [PMID: 15378055]
[25]
Pang J, Xu F, Aondio G, et al. Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat Commun 2021; 12(1): 814.
[http://dx.doi.org/10.1038/s41467-021-21085-8] [PMID: 33547300]
[26]
Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995; 77(3): 638-43.
[http://dx.doi.org/10.1161/01.RES.77.3.638] [PMID: 7641334]
[27]
Li C, Ye J, Chen Q, et al. Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19. Aging (Albany NY) 2020; 12(15): 15670-81.
[http://dx.doi.org/10.18632/aging.103770] [PMID: 32805722]
[28]
Imran MM, Ahmad U, Usman U, Ali M, Shaukat A, Gul N. Retracted: Neutrophil/lymphocyte ratio—A marker of COVID-19 pneumonia severity. Int J Clin Pract 2021; 75(4): e13698.
[http://dx.doi.org/10.1111/ijcp.13698] [PMID: 32892477]
[29]
Komolafe O, Pereira SP, Davidson BR, Gurusamy KS. Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis. Cochrane Database Syst Rev 2027; 2017(4): CD012645.
[30]
Van Wilpe S, Koornstra R, Den Brok M, et al. Lactate dehydrogenase: A marker of diminished antitumor immunity. OncoImmunology 2020; 9(1): 1731942.
[http://dx.doi.org/10.1080/2162402X.2020.1731942] [PMID: 32158624]
[31]
Pourfathi M, Cereda M, Chatterjee S, et al. Lung metabolism and inflammation during mechanical ventilation; an imaging approach. Sci Rep 2018; 8(1): 3525.
[http://dx.doi.org/10.1038/s41598-018-21901-0] [PMID: 29476083]
[32]
Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect Dis 2013; 13(9): 752-61.
[http://dx.doi.org/10.1016/S1473-3099(13)70204-4] [PMID: 23891402]
[33]
Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical Characteristics of Refractory Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2021; 73(11): e4208-13.
[34]
Zhang R, Ouyang H, Fu L, et al. CT features of SARS-CoV-2 pneumonia according to clinical presentation: A retrospective analysis of 120 consecutive patients from Wuhan city. Eur Radiol 2020; 30(8): 4417-26.
[http://dx.doi.org/10.1007/s00330-020-06854-1] [PMID: 32279115]
[35]
Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J 2020; 55(5): 2000547.
[36]
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020; 368: m1091.
[http://dx.doi.org/10.1136/bmj.m1091] [PMID: 32217556]
[37]
Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63(3): 364-74.
[http://dx.doi.org/10.1007/s11427-020-1643-8] [PMID: 32048163]
[38]
Vargas-Vargas M, Cortés-Rojo C. Ferritin levels and COVID-19. Rev Panam Salud Publica 2020; 44: 1.
[http://dx.doi.org/10.26633/RPSP.2020.72] [PMID: 32547616]
[39]
Lin Z, Long F, Yang Y, Chen X, Xu L, Yang M. Serum ferritin as an independent risk factor for severity in COVID-19 patients. J Infect 2020; 81(4): 647-79.
[http://dx.doi.org/10.1016/j.jinf.2020.06.053] [PMID: 32592705]
[40]
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020; 295(15): 4773-9.
[http://dx.doi.org/10.1074/jbc.AC120.013056] [PMID: 32094225]
[41]
Administration UFD. Remdesivir emergency use authorization letter. 2020.
[42]
Choy KT, Wong AYL, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 2020; 178: 104786.
[http://dx.doi.org/10.1016/j.antiviral.2020.104786] [PMID: 32251767]
[43]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy